Mai Capital Management Lineage Cell Therapeutics, Inc. Transaction History
Mai Capital Management
- $9.87 Billion
- Q2 2024
A detailed history of Mai Capital Management transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Mai Capital Management holds 1,638,772 shares of LCTX stock, worth $1.51 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,638,772
Previous 1,490,862
9.92%
Holding current value
$1.51 Million
Previous $2.21 Million
25.75%
% of portfolio
0.02%
Previous 0.02%
Shares
9 transactions
Others Institutions Holding LCTX
# of Institutions
121Shares Held
94.3MCall Options Held
31.3KPut Options Held
400-
Broadwood Capital Inc New York, NY41.7MShares$38.3 Million3.19% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$8.79 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.47MShares$7.8 Million0.0% of portfolio
-
Defender Capital, Llc.4.97MShares$4.58 Million1.77% of portfolio
-
Logos Global Management LP San Francisco, CA4.7MShares$4.32 Million0.44% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $156M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...